XML 56 R34.htm IDEA: XBRL DOCUMENT v3.25.3
Revenues (Tables)
 12 Months Ended
Sep. 30, 2025
Revenue from Contract with Customer [Abstract]  
Summary of Contract Balances
The following table summarizes our contract balances:
September 30,
(in thousands) 20252024
Contract assets(1)
$3,857 $2,031 
Contract liabilities(2)
6,884 2,131 
(1) Consists of unbilled amounts primarily related to Biopharma contracts which consists of research and development agreements with third parties.
(2) Consists of receipt of advance payments before our performance obligations related to revenue contracts are met.
Summary of Revenue by Geographic Region
The table below sets forth revenues by geographic region, based on ship-to destinations. Americas consists of the United States, Canada, Mexico and South America; EMEA consists of Europe, the Middle East, and Africa; and APAC primarily consists of Japan, China, South Korea, India, Singapore, Malaysia and Australia.
Year ended September 30,
(in thousands)202520242023
Americas$225,580 $193,884 $151,263 
EMEA124,240 92,567 71,389 
APAC26,752 26,523 22,457 
Total$376,572 $312,974 $245,109 
Summary of Revenue by Product
The table below sets forth revenues by products.
Year ended September 30,
(in thousands)202520242023
Synthetic genes$113,602 $92,679 $73,541 
Oligo pools20,230 16,906 14,489 
DNA libraries11,184 13,933 10,201 
Antibody discovery23,452 20,328 23,172 
NGS tools208,104 169,128 123,706 
Total$376,572 $312,974 $245,109 
Summary of Revenue by Industry
The table below sets forth revenues by industry.
Year ended September 30,
(in thousands)202520242023
Industrial chemicals/materials$93,246 $83,472 $59,321 
Academic research65,861 58,452 45,847 
Healthcare215,092 168,959 137,148 
Food/agriculture2,373 2,091 2,793 
Total revenues$376,572 $312,974 $245,109